Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency
Status:
Completed
Trial end date:
2018-03-28
Target enrollment:
Participant gender:
Summary
The study has been designed to establish the pharmacokinetics (PK) and iron uptake of Ferric
Maltol in children and adolescents aged 10-17 years using two (2) lower dose strengths in
comparison to the EU-approved 30mg BID dose in adults with IDA in IBD.